Patents Assigned to Merck Sharp & Dohme
  • INSULIN-INCRETIN CONJUGATES
    Publication number: 20230105982
    Abstract: Insulin-incretin conjugates comprising a peptide having agonist activity at the glucagon-like 1 (GLP-1) receptor, the glucagon (GCG) receptor, and/or the gastric inhibitory protein (GIP) receptor conjugated to an insulin molecule having agonist activity at the insulin receptor and use of the conjugates for treatment of metabolic diseases, for example, Type 2 diabetes, are described.
    Type: Application
    Filed: July 28, 2021
    Publication date: April 6, 2023
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Anandan Palani, Chunhui Huang, Zhiqiang Yang, Lin Yan, Songnian Lin, Pei Huo, Qiaolin Deng, Elisabetta Bianchi, Federica Orvieto
  • NON-INVASIVE CONTINUOUS CAPACITANCE LEVEL DETECTOR
    Publication number: 20230103467
    Abstract: The present invention relates to a non-invasive Capacitance Level Detector useful for continuous detection of the level and/or mass of a non-conductive or weakly-conductive bulk material in a vessel, and methods of using the detector.
    Type: Application
    Filed: December 11, 2020
    Publication date: April 6, 2023
    Applicant: Merck Sharp & Dohme LLC
    Inventors: William Blincoe, Michael Yves Louge, Jasdeep Mandur, Anthony S. Tantuccio
  • PNEUMOCOCCAL POLYSACCHARIDES AND THEIR USE IN IMMUNOGENIC POLYSACCHARIDE-CARRIER PROTEIN CONJUGATES
    Publication number: 20230107713
    Abstract: The present invention provides capsular polysaccharides from Streptococcus pneumoniae serotypes identified using NMR The present invention further provides polysaccharide-protein conjugates in which capsular polysaccharides from one or more of these serotypes are conjugated to a carrier protein such as CRM197. Polysaccharide-protein conjugates from one or more of these serotypes may be included in multivalent pneumococcal conjugate vaccines having polysaccharides from multiple additional Streptococcus pneumoniae serotypes.
    Type: Application
    Filed: September 22, 2022
    Publication date: April 6, 2023
    Applicant: Merck Sharp & Dohme LLC
    Inventors: Richard J. Porambo, Chitrananda Abeygunawardana, Luwy Kavuka Musey, Michael J. Kosinski, Yadong Adam Cui, Julie Marie Skinner
  • PNEUMOCOCCAL POLYSACCHARIDES AND THEIR USE IN IMMUNOGENIC POLYSACCHARIDE-CARRIER PROTEIN CONJUGATES
    Publication number: 20230094548
    Abstract: The present invention provides capsular polysaccharides from Streptococcus pneumoniae serotypes identified using NMR. The present invention further provides polysaccharide-protein conjugates in which capsular polysaccharides from one or more of these serotypes are conjugated to a carrier protein such as CRM197. Polysaccharide-protein conjugates from one or more of these serotypes may be included in multivalent pneumococcal conjugate vaccines having polysaccharides from multiple additional Streptococcus pneumoniae serotypes.
    Type: Application
    Filed: September 27, 2022
    Publication date: March 30, 2023
    Applicant: Merck Sharp & Dohme LLC
    Inventors: Richard J. Porambo, Chitrananda Abeygunawardana, Luwy Kavuka Musey, Michael J. Kosinski, Yadong Adam Cui, Julie Marie Skinner
  • ANTIBODY DRUG CONJUGATE FOR ANTI-INFLAMMATORY APPLICATIONS
    Publication number: 20230099074
    Abstract: Antibody drug conjugates (ADCs) comprising an antibody conjugated to an anti-inflammatory therapeutic agent via a phosphate-based linker with tunable extracellular and intracellular stability are described.
    Type: Application
    Filed: October 26, 2022
    Publication date: March 30, 2023
    Applicants: Merck Sharp & Dohme LLC, Ambrx, Inc.
    Inventors: Philip E. Brandish, Robert M. Garbaccio, Jeffrey Kern, Linda Liang, Sanjiv Shah, Dennis Zaller, Andrew Beck, Dennis Gately, Nick Knudsen, Anthony Manibusan, Jianing Wang, Ying Sun
  • HUMAN-LIKE HEAVY CHAIN ANTIBODY VARIABLE DOMAIN (VHH) DISPLAY LIBRARIES
    Publication number: 20230102101
    Abstract: Heavy chain antibody variable domain (VHH) display libraries are described comprising human-like VHH comprising three synthetically generated complementarity determining region (CDR) areas in which the amino acids at each of positions 44 and 45 or positions 37, 44, 45, and 47 comprise the amino acid at the corresponding position of a Camelid VHH, wherein the amino acid positions are according to Kabat numbering Human-like VHHs identified using these libraries may be useful for the manufacture of therapeutics for treating diseases and disorders.
    Type: Application
    Filed: March 1, 2021
    Publication date: March 30, 2023
    Applicant: Merck Sharp & Dohme LLC
    Inventors: Lei Chen, Ming-Tang Chen, Chung-Ming Hsieh, Alexander Mario Sevy
  • DRUG DELIVERY SYSTEM FOR THE DELIVERY OF STEROID TO VITREOUS CHAMBER OF THE EYE
    Publication number: 20230086256
    Abstract: This invention relates to novel implant drug delivery systems for long-acting delivery of mometasone furoate. These compositions are useful for the treatment or prevention of inflammatory conditions of the eye.
    Type: Application
    Filed: January 22, 2021
    Publication date: March 23, 2023
    Applicant: Merck Sharp & Dohme LLC
    Inventors: Morgan B. Giles, Seth P. Forster, Stephanie Elizabeth Barrett, Steven C. Persak
  • IN SILICO PROCESS FOR SELECTING PROTEIN FORMULATION EXCIPIENTS
    Publication number: 20230093392
    Abstract: The invention relates to an in silico screening method to identify candidate excipients for reducing aggregation of a protein in a formulation. The method combines computational molecular modeling and molecular dynamics simulations to identify sites on a protein where non-specific self-interaction and interaction of different test excipients may occur, determine the relative binding energies of such interactions, and select one or more test excipients that meet specified interaction criteria for use as candidate excipients in empirical screening studies.
    Type: Application
    Filed: November 4, 2022
    Publication date: March 23, 2023
    Applicant: Merck Sharp & Dohme LLC
    Inventors: Francis Insaidoo, David Roush
  • PATIENT TRAINING DEVICE FOR USE WITH A SAFETY SYRINGE INJECTOR
    Publication number: 20230086278
    Abstract: The present invention provides reusable safety syringe devices for use as a teaching and practice tool. The safety syringe device of the present invention comprises four primary parts: (1) a first tubular member; (2) a second tubular member disposed within an inner annular cavity of the first tubular member; (3) a syringe secured within an inner annular cavity of the second tubular member; and (4) a plunger rod, wherein the plunger rod comprises a proximal end and a distal end, wherein the proximal end and distal end are connected by a shaft, wherein the proximal end comprises a first plunger rod flange having a first diameter and a removable second plunger rod flange having a second diameter, wherein the first diameter is smaller than the second diameter and the first plunger rod flange is located below the second plunger rod flange on the shaft.
    Type: Application
    Filed: February 9, 2021
    Publication date: March 23, 2023
    Applicant: Merck Sharp & Dohme LLC
    Inventors: John B. CLINE, Cassie MEGNA, Wail RASHEED
  • METHODS FOR TREATING CANCER OR INFECTION USING A COMBINATION OF AN ANTI-PD-1 ANTIBODY, AN ANTI-CTLA4 ANTIBODY, AND AN ANTI-TIGIT ANTIBODY
    Publication number: 20230092707
    Abstract: Provided herein are methods of treating a cancer, an infectious disease or infection, which comprise administering to a subject in need thereof a combination of agents: (a) an anti-human PD-1 antibody or antigen binding fragment thereof; (b) an anti-human CTLA4 antibody or antigen binding fragment thereof; and (c) an anti-human TIGIT antibody or antigen binding fragment thereof. Also provided are therapeutic combinations for use, pharmaceutical compositions and kits containing such agents for the treatment of a cancer, an infectious disease, or an infection.
    Type: Application
    Filed: March 4, 2021
    Publication date: March 23, 2023
    Applicant: MERCK SHARP & DOHME LLC
    Inventors: Rachel A. Altura, Mingmei Cai, Scott J. Diede, Jane Anne Healy, Blanca Homet Moreno, Nageatte Ibrahim, Sybil M.G. Williams
  • METHODS FOR PRODUCING STREPTOCOCCUS PNEUMONIAE CAPSULAR POLYSACCHARIDE CARRIER PROTEIN CONJUGATES
    Publication number: 20230077640
    Abstract: A method is described for producing a pneumococcal capsular polysaccharide protein conjugate in which one or more activated pneumococcal polysaccharides of particular pneumococcal serotypes and carrier protein are separately lyophilized, the separately lyophilized polysaccharides and carrier protein are separately reconstituted in an organic solvent, and the reconstituted polysaccharide and carrier protein are then combined together by Tee-mixing and conjugated together to produce polysaccharide carrier protein conjugates. A plurality of conjugates, each comprising polysaccharides of a particular serotype, may be used to produce multivalent pneumococcal immunogenic compositions having a combination of conjugates for use in vaccines.
    Type: Application
    Filed: October 25, 2022
    Publication date: March 16, 2023
    Applicant: Merck Sharp & Dohme LLC
    Inventors: Patrick Leonard Ahl, Akhilesh Bhambhani, Christopher Jon Farrell, Patrick McHugh, Morrisa C. Jones, Daniel D. Roth, Jessica R. Sinacola, Justin Stanbro, Matthew P. Watson, Emily Wen, Michael A. Winters
  • MACROCYCLIC PEPTIDES AS POTENT INHIBITORS OF K-RAS G12D MUTANT
    Publication number: 20230083431
    Abstract: The invention provides compounds of the Formula (I) or pharmaceutically acceptable salts thereof, wherein the variables are as described herein. The compounds or their pharmaceutically acceptable salts can inhibit the G12D mutant of Kirsten rat sarcoma (K-Ras) protein and are expected to have utility as therapeutic agents, for example, for treating cancer. The invention also provides pharmaceutical compositions which comprise compounds of Formula (I) or pharmaceutically acceptable salts thereof. The invention also relates to methods for use of the compounds or their pharmaceutically acceptable salts in the therapy and prophylaxis of cancer and for preparing pharmaceuticals for this purpose.
    Type: Application
    Filed: December 15, 2020
    Publication date: March 16, 2023
    Applicants: Merck Sharp & Dohme LLC, MSD International GMBH (Singapore Branch), Agency for Science, Technology and Research
    Inventors: Nicolas C. Boyer, Michael B. Garrigou, Sookhee Nicole Ha, Chunhui Huang, Anthony W. Partridge, Tomi K. Sawyer, Pietro Aronica, Charles W. Johannes, Srinivasaraghavan Kannan, Chandra S. Verma, Tsz Ying Yuen
  • AMIDO-SUBSTITUTED HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF HERPES VIRUSES
    Publication number: 20230077499
    Abstract: The present invention relates to novel Amido-Substituted Heterocycle Compounds of Formula (I) and pharmaceutically acceptable salts thereof, wherein X, R1, R2, R3, and R4 are as defined herein. The present invention also relates to compositions comprising at least one Amido-Substituted Heterocycle Compound, and methods of using the Amido-Substituted Heterocycle Compounds for treating or preventing a herpesvirus infection in a patient.
    Type: Application
    Filed: December 16, 2020
    Publication date: March 16, 2023
    Applicant: Merck Sharp & Dohme LLC
    Inventors: Kira A. Armacost, Andrew John Cooke, Robert Patrick Hayes, Marc A. Labroli, Michael Aaron Plotkin, Izzat Tiedje Raheem, Jeffrey W. Schubert, David M. Tellers
  • METHODS OF SEPARATING HOST CELL LIPASES FROM AN ANTI-LAG3 ANTIBODY PRODUCTION
    Publication number: 20230077205
    Abstract: Provided herein are methods of separating host cell lipases from an anti-LAG3 antibody or antigen binding fragment in chromatographic processes and methods of improving polysorbate-80 stability in an anti-LAG3 antibody formulation by separating host cell lipases from the anti-LAG3 antibody or antigen binding fragment using chromatographic processes. Also provided are pharmaceutical compositions comprising an anti-LAG3 antibody or antigen binding fragment and less than 2 ppm of a host cell lipase.
    Type: Application
    Filed: January 28, 2021
    Publication date: March 9, 2023
    Applicant: Merck Sharp & Dohme LLC
    Inventors: Colette M. CUTLER, Hong LI, Sketa PATEL, Sandra E. RIOS, John P. WELSH
  • METHODS FOR MONITORING THE PROGRESS OF POLYSACCHARIDE SIZE-REDUCTION
    Publication number: 20230073288
    Abstract: The present invention relates to Polysaccharide Size-Reduction Monitoring Methods useful for the non-invasive, and accurate monitoring of the progress of a polysaccharide size-reduction process.
    Type: Application
    Filed: February 24, 2021
    Publication date: March 9, 2023
    Applicant: Merck Sharp & Dohme LLC
    Inventors: Jennifer C. P. Wang, Kelsey A. Richards, Jayesh Desai, Bhumit A. Patel, Michael A. Winters, Patrick M. McHugh, Philip R. Kuhl, John P. Higgins, Michael I. Larkin, Michelle H. Chen
  • PNEUMOCOCCAL POLYSACCHARIDES AND THEIR USE IN IMMUNOGENIC POLYSACCHARIDE-CARRIER PROTEIN CONJUGATES
    Publication number: 20230075760
    Abstract: The present invention provides capsular polysaccharides from Streptococcus pneumoniae serotypes identified using NMR. The present invention further provides polysaccharide-protein conjugates in which capsular polysaccharides from one or more of these serotypes are conjugated to a carrier protein such as CRM197. Polysaccharide-protein conjugates from one or more of these serotypes may be included in multivalent pneumococcal conjugate vaccines having polysaccharides from multiple additional Streptococcus pneumoniae serotypes.
    Type: Application
    Filed: September 22, 2022
    Publication date: March 9, 2023
    Applicant: Merck Sharp & Dohme LLC
    Inventors: Richard J. Porambo, Chitrananda Abeygunawardana, Luwy Kavuka Musey, Michael J. Kosinski, Yadong Adam Cui, Julie Marie Skinner
  • FORMULATIONS OF DENGUE VIRUS VACCINE COMPOSITIONS
    Publication number: 20230061673
    Abstract: The present invention relates to formulations of dengue virus vaccine comprising at least one live, attenuated dengue virus or live, attenuated chimeric flavivirus, a buffer, a sugar, a cellulose derivative, a glycol or sugar alcohol, optionally an alkali or alkaline salt and an amino acid; and formulations of dengue virus vaccine comprising at least one live, attenuated dengue virus or live, attenuated chimeric flavivirus, a buffer, a sugar of at least 150 mg/ml, a carrier, and optionally an alkali or alkaline salt and an amino acid.
    Type: Application
    Filed: July 26, 2022
    Publication date: March 2, 2023
    Applicant: Merck Sharp & Dohme LLC
    Inventors: Michael S. Ryan, Sherrie-Ann P. Martin, Morrisa Jones, Justin Stanbro, Akhilesh Bhambhani, Jeffrey Thomas Blue, Heidi Joanne Pixley, Erin J. Green-Trexler, Lynne Ann Isopi
  • INDAZOLE DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF HERPES VIRUSES
    Publication number: 20230066268
    Abstract: The present invention relates to novel Indazole Derivatives of Formula (I): and pharmaceutically acceptable salts thereof, wherein A, X, Y, Z, R1 R5 and R6 are as defined herein. The present invention also relates to compositions comprising at least one Indazole Derivative, and methods of using the Indazole Derivatives for treating or preventing a herpesvirus infection in a patient.
    Type: Application
    Filed: December 15, 2020
    Publication date: March 2, 2023
    Applicant: Merck Sharp & Dohme LLC
    Inventors: Andrew John Cooke, Christopher D. Cox, Scott D. Edmondson, Charles Lee Jayne, Anilkumar G. Nair, Jeffrey W. Schubert, Jason W. Skudlarek, David M. Tellers, De-Yi Yang
  • STAPLED TRIAZOLE CO-AGONISTS OF THE GLUCAGON AND GLP-1 RECEPTORS
    Publication number: 20230063794
    Abstract: The stapled peptides of the present invention, and pharmaceutically acceptable salts thereof, are co-agonists of the glucagon and GLP-1 receptors, and may be useful in the treatment, prevention and suppression of diseases mediated by the glucagon receptor and the GLP-1 receptor, including but not limited to, metabolic disorders such as diabetes, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and obesity.
    Type: Application
    Filed: December 18, 2020
    Publication date: March 2, 2023
    Applicant: Merck Sharp & Dohme LLC
    Inventors: Elisabetta Bianchi, Qiaolin Deng, Songnian Lin, Federica Orvieto, Anandan Palani, Antonello Pessi, Tomi K. Sawyer
  • USE OF BIOMARKERS IN IDENTIFYING PATIENTS THAT WILL BE RESPONSIVE TO TREATMENT WITH A PRMT5 INHIBITOR
    Publication number: 20230062119
    Abstract: The present invention includes methods of identifying a patient who will likely be responsive to treatment with a protein arginine N-methyltransferase 5 inhibitor, or a pharmaceutically acceptable salt thereof, and methods of treating the same.
    Type: Application
    Filed: December 16, 2020
    Publication date: March 2, 2023
    Applicant: Merck Sharp & Dohme LLC
    Inventors: Benjamin Nicholson, Rachel Allison Altura, Razvan Cristescu, David John Curtis, Ian Philip Street